Available Technologies
# of Displayed Technologies: 7 / 7
Applied Category Filter (Click To Remove): Gene Therapy
Innovative Solutions for Cell Viability and Targeted Delivery
TS-066100 — Research tool to transfect cells ex vivo using electroporation through electrospun core-shell fibers for research applications
The Need:
Conventional electroporation methods often result in low cell viability due to heat generation, especially when working with primary cells. These methods also face challenges with non-specific transport of molecules, high vector integration rates leading to mutagenesis, and inefficacy in …
- College: College of Engineering (COE)
- Inventors: Gallego Perez, Daniel; Das, Devleena; Duarte Sanmiguel, Silvia; Higuita Castro, Natalia
- Licensing Officer: Willson, Christopher
T-cells with Enhanced Ability to Respond to Exogenous Ligands
TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.
The Need
As interest in cell-based therapies, particularly for cancer treatment, continues to rise, there’s a critical need for therapeutic cells capable of robust proliferation in vivo. Existing methods relying on exogenous cytokines like IL-2 face challenges due to dose-limiting toxicity an…
- College: OSU Wexner Medical Center
- Inventors: Rubinstein, Mark
- Licensing Officer: Willson, Christopher
Gene Therapy Approach for Treating Neuropathy
TS-065913 — Gene therapy strategies for treating peripheral neuropathy.
Peripheral neuropathy (PN) results in loss of innervation by the peripheral nerves in tissues such as skin, muscle, heart, and adipose tissue. It is a painful, debilitating disease, that is estimated to affect between 20 and 30 million Americans. The number of Americans affected by PN is likely muc…
- College: College of Medicine (COM)
- Inventors: Townsend, Kristy; Blaszkiewicz, Magdalena; Cao, Lei
- Licensing Officer: Willson, Christopher
Gene Therapy Compositions for Treating Cardiovascular Diseases
TS-063091 — A gene therapy approach to address the specific needs of failing hearts.
Heart failure affects over 6 million adults in the US and can lead to irreversible damage to the heart.
The Need
In the realm of cardiovascular health and the management of heart-related disorders, there exists a pressing commercial need for a technology that can effectively address the challenge…
- College: College of Medicine (COM)
- Inventors: Lewandowski, E. Douglas; Carley, Andrew
- Licensing Officer: Willson, Christopher
Treating Obesity and Cardiovascular Disease Via Genetic Manipulation of Skin Tissue
TS-062096 — Using tissue nano-transfection to regulate BAT and increase 12,13-diHOME production to treat obesity, cardiovascular disease and type 2 diabetes.
Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all adults in the US. CVD encompasses a number of conditions that affect the heart and vasculature. CVD can arise in response to multiple factors, including obesity. Obesity elevates the…
- College: College of Medicine (COM)
- Inventors: Stanford, Kristin; Gallego Perez, Daniel; Ziolo, Mark
- Licensing Officer: Willson, Christopher
An improved base editor (iABE-NG) for correcting genetic diseases such as Duchenne muscular dystrophy
TS-049505 — An engineered base editor (iABE-NG) that uses an SpCas9 variant, a shortened adenine deaminase domain with eliminated RNA off-target activity, and an intein split for packaging into an adeno-associated virus (AAV), resulting in gene mutation correction.
There are thousands of monogenic diseases that are lacking effective therapeutic treatments. The main bottleneck in developing effective treatment is the ability to effectively edit gene while controlling for the myriad of off-target effects that come with targeting the genome. Duchenne Muscular D…
- College: College of Medicine (COM)
- Inventors: Han, Renzhi; Gao, Yandi; Xu, Li
- Licensing Officer: Schworer, Adam
LNA Inhibitor Cocktail Therapy for Lupus
TS-037260 — A cocktail of locked nucleic acids inhibits the inflammatory response in a humanized murine model of lupus.
Systemic lupus erythematosus (SLE) is an orphan disease affecting approximately 5 in every 10,000 individuals. Despite its rare prevalence, this lifelong autoimmune disease has few effective targeted therapies. Current treatments are palliative using anti-inflammatory drugs or broad spectrum immun…
- College: College of Medicine (COM)
- Inventors: Jarjour, Wael; Valiente, Giancarlo; Young, Nicholas
- Licensing Officer: He, Panqing
